These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37194405)
1. Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease. Pandey A; Raja R; Estepp JH; Ramkrishna D CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):748-757. PubMed ID: 37194405 [TBL] [Abstract][Full Text] [Related]
2. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study. Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291 [TBL] [Abstract][Full Text] [Related]
3. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Hodges JR; Phillips SM; Norell S; Nwosu C; Khan H; Luo L; Badawy SM; King A; Tanabe P; Treadwell M; Rojas Smith L; Calhoun C; Hankins JS; Porter J Blood Adv; 2020 Sep; 4(18):4463-4473. PubMed ID: 32941646 [TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy in children severely affected with sickle cell disease. Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542 [TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Nevitt SJ; Jones AP; Howard J Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137 [TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease. Green NS; Manwani D; Aygun B; Appiah-Kubi A; Smith-Whitley K; Castillo Y; Soriano L; Jia H; Smaldone AM Pediatr Blood Cancer; 2024 Apr; 71(4):e30878. PubMed ID: 38321562 [TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges. Dexter D; McGann PT Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823 [TBL] [Abstract][Full Text] [Related]
9. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791 [TBL] [Abstract][Full Text] [Related]
10. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965 [TBL] [Abstract][Full Text] [Related]
11. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582 [TBL] [Abstract][Full Text] [Related]
12. Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia. Creary SE; Beeman C; Stanek J; King K; McGann PT; O'Brien SH; Liem RI; Holl J; Badawy SM Pediatr Blood Cancer; 2022 Jun; 69(6):e29607. PubMed ID: 35373884 [TBL] [Abstract][Full Text] [Related]
13. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease. Kang HA; Barner JC J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448 [No Abstract] [Full Text] [Related]
14. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Estepp JH; Winter B; Johnson M; Smeltzer MP; Howard SC; Hankins JS Pediatr Blood Cancer; 2014 Nov; 61(11):2031-6. PubMed ID: 25132074 [TBL] [Abstract][Full Text] [Related]
15. Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease. Creary SE; Modi AC; Stanek JR; Chisolm DJ; O'Brien SH; Nwankwo C; Crosby LE J Pediatr Psychol; 2019 Nov; 44(10):1196-1204. PubMed ID: 31403687 [TBL] [Abstract][Full Text] [Related]
16. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol. Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480 [TBL] [Abstract][Full Text] [Related]
17. Interventions for chronic kidney disease in people with sickle cell disease. Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087 [TBL] [Abstract][Full Text] [Related]
18. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach. Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683 [TBL] [Abstract][Full Text] [Related]
19. Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease. Creary S; Chisolm D; Stanek J; Neville K; Garg U; Hankins JS; O'Brien SH Pediatr Blood Cancer; 2020 Aug; 67(8):e28250. PubMed ID: 32386106 [TBL] [Abstract][Full Text] [Related]
20. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]